1,193 research outputs found
Ashley Chilton Interview - Part 1 (Henry County)
No full textAn interview with Ashley Chilton by Robert M. Rennick on the place names of communities in Henry County, Kentucky
Ashley Chilton Interview - Part 2 (Henry County)
No full textAn interview with Ashley Chilton by Robert M. Rennick on the place names of communities in Henry County, Kentucky
Oral history interview with Robert G. Chilton
No full textManned Spacecraft Center Guidance and Control; NASA and MSC politics and personality conflicts
Letter from Robert Jemison, Jr., Tuskaloosa, Alabama to Honorable W. P. Chilton, Richmond, Virginia, August 27, 1862
No full textLetter from Robert Jemison, Jr., Tuskaloosa, Alabama to Honorable W. P. Chilton and Company, Richmond, Virginia, September 7, 1862
No full textC. W. Chilton, Diogenes of Oenoanda. The Fragments. A Translation and Commentary
No full textJoly Robert. C. W. Chilton, Diogenes of Oenoanda. The Fragments. A Translation and Commentary. In: L'antiquité classique, Tome 41, fasc. 1, 1972. p. 377
Distance measurement by inertial means
No full textThesis (M.S.) Massachusetts Institute of Technology. Dept. of Aeronautical Engineering, 1949.Bibliography: leaf 44.by Robert G. Chilton and Alfred R. Seville.M.S
Practical strategies for improving outcomes in T2DM: The potential role of pioglitazone and DPP4 inhibitors
No full textT2DM is a complex disease underlined by multiple pathogenic defects responsible for the development and progression of hyperglycaemia. Each of these factors can now be tackled in a more targeted manner thanks to glucose-lowering drugs that have been made available in the past 2 to 3 decades. Recognition of the multiplicity of the mechanisms underlying hyperglycaemia calls for treatments that address more than 1 of these mechanisms, with more emphasis placed on the earlier use of combination therapies. Although chronic hyperglycaemia contributes to and amplifies cardiovascular risk, several trials have failed to show a marked effect from intensive glycaemic control. During the past 10 years, the effect of specific glucose-lowering agents on cardiovascular risk has been explored with dedicated trials. Overall, the cardiovascular safety of the new glucose-lowering agents has been proven with some of the trials summarized in this review, showing significant reduction of cardiovascular risk. Against this background, pioglitazone, in addition to exerting a sustained glucose-lowering effect, also has ancillary metabolic actions of potential interest in addressing the cardiovascular risk of T2DM, such as preservation of beta-cell mass and function. As such, it seems a logical agent to combine with other oral anti-hyperglycaemic agents, including dipeptidyl peptidase-4 inhibitors (DPP4i). DPP4i, which may also have a potential to preserve beta-cell function, is available as a fixed-dose combination with pioglitazone, and could, potentially, attenuate some of the side effects of pioglitazone, particularly if a lower dose of the thiazolidinedione is used. This review critically discusses the potential for early combination of pioglitazone and DPP4i
Letter from Rev. Humphreys Requesting Langston Church of the Holy Family Episcopal Church
No full textMarch 7, 1963, letter from Rev. Robert A Laud Humpreys to Rt. Rev. Chilton Powell requesting a campus ministry and community church be established on the campus of Langston University
Adine Chilton Calvin
No full textFirst wife of author, Ross Calvin. Adine Chilton Calvin died of influenza on December 18, 1918 at the age of 28. Photograph comes from the book written by Ross Calvin, "A Mystical Bride" available on New Mexico Digital Collections. NOTE: CSWR only has digital copy
- …
